Stay updated on Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial

Sign up to get notified when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The study page now lists melanoma among related topics from MedlinePlus Genetics, and the site revision label advances from v3.8.0 to v3.8.1.
    Difference
    0.1%
    Check dated 2026-11-18T00:58:19.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the completed CheckMate 238 melanoma study is now displayed, including study design, participant criteria, outcomes, and locations. It also provides related publications and study documents.
    Difference
    100%
    Check dated 2026-11-10T19:38:47.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.2 to v3.8.0, while the study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T19:54:16.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    An NIH-wide banner about terminology changes during a transition appeared, and the site revision advanced from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T20:26:10.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-06T20:54:05.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record content. The surrounding header and navigation remain visible, but the main study information is not accessible.
    Difference
    18%
    Check dated 2026-09-22T22:52:41.000Z thumbnail image

Stay in the know with updates to Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.